论文部分内容阅读
普遍认为引起肆虐全球的HIV/AIDS大流行的病原体HIV是不可治愈并且是致命的。自从 20多年前发现并分离出病毒后,全世界在生产预防性和治疗性疫苗的努力至今都是失败的。作者在尼日利亚设计开发了HIV疫苗,并且已经应用这些疫苗分别对知情同意的HIV感染者和正常人进行了试验。在许多病例中,治疗性疫苗不仅在HIV感染的症状上产生了快速的改善,而且许多患者持续的抗 HIV抗体血清转阴。在那些并发HBV和 /或HCV感染的HIV患者中,治疗性疫苗产生了持续的抗HBsAg和抗HCV抗体转阴。使用这些疫苗至今没有观察到显著的不良反应,也没有引起可检测的标志性抗 HIV抗体产生。推测这种疫苗可诱导针对HIV、HBV和HCV感染细胞有效的选择性的细胞介导的细胞毒性免疫应答。
It is generally accepted that HIV, the causative agent of the HIV / AIDS pandemic that rages throughout the world, is incurable and fatal. Since the discovery and isolation of the virus more than 20 years ago, the world’s efforts to produce prophylactic and therapeutic vaccines have so far failed. The authors designed and developed HIV vaccines in Nigeria and have used these vaccines to test informed consent of HIV-infected individuals and normal individuals, respectively. In many cases, therapeutic vaccines not only produced rapid improvements in the symptoms of HIV infection, but many continued anti-HIV antibody seroconversion. In those patients with HIV that are complicated by HBV and / or HCV infection, the therapeutic vaccine produces persistent anti-HBsAg and anti-HCV antibody negatives. To date, no significant adverse effects have been observed with these vaccines nor have detectible markers of anti-HIV antibody production been established. It is speculated that this vaccine induces a potent and selective cell-mediated cytotoxic immune response against HIV, HBV and HCV infected cells.